Pure Global
NCT00127049

Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors

A Prospective Multicenter Phase II Trial of Gemcitabine, Cisplatin, and Ifosfamide (GIP) in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors (NSGCT) and a Predicted Favorable Prognosis
Gustave Roussy, Cancer Campus, Grand Paris·Phase 2·ClinicalTrials.gov·drug
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Germ Cell Tumor
Drug/Device/Intervention
gemcitabine, ifosfamide, cisplatin, G-CSF
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Location
Villejuif, France
Timeline & enrollment
Phase
Phase 2
Start date
Dec 01, 2004
End date
N/A
Enrollment
37 participants
Primary outcome

Complete response rate

Summary

This is a prospective multicenter phase II trial of gemcitabine, cisplatin, and ifosfamide
 (GIP) in patients with relapsed non-seminomatous germ-cell tumors (NSGCT) and a predicted
 favorable prognosis.

ICD-10 classifications
Malignant neoplasmsMalignant neoplasm: JejunumMalignant neoplasm: PrepuceMalignant neoplasm: Female genital organ, unspecifiedMalignant neoplasm: Vulva, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT00127049
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT00127049 through Pure Global AI's free database. This Phase 2 trial is sponsored by Gustave Roussy, Cancer Campus, Grand Paris and is currently status unknown. The study focuses on Germ Cell Tumor. Target enrollment is 37 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.